Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Jan 16, 2008

Akrimax Purchases Wyeth’s Rouses Point Facility

  • Akrimax Pharmaceuticals bought Wyeth’s drug manufacturing and packaging plant in Rouses Point, NY. In late 2005, Wyeth decided to phase out operations at this site. Akrimax’ acquisition thus averts closure of the plant.

    Wyeth and Akrimax will have a cooperative relationship during a transition period that will conclude at the end of 2009. During this time, Akrimax will lease the facility back to Wyeth, so that Wyeth can continue manufacturing its products, while Akrimax begins integrating its own products into the facility.

    “Our plan is to develop, manufacture, and distribute pharmaceutical products from our own product portfolio and other third-party contracts,” says Joseph Krivulka, one of the Akrimax founders.



Be sure to take the GEN Poll

CRISPR Patent Controversy

Do you think recently released email from a former Broad Institute scientist to Jennifer Doudna will expedite a final legal decision on who owns the CRISPR patent?

More »